查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370946

病毒载体生产 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按载体类型、工作流程、按应用、最终用户、地区、竞争细分

Viral Vector Production - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Vector Type, By Workflow, By Application, By End User, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 178 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022年全球病毒载体生产市场估值为52.2亿美元，预计在预测期内将大幅成长，预计复合年增长率（CAGR）为14.21%，预计到2028年将达到115.4亿美元。载体生产需要创建和製造改良病毒（称为病毒载体），用于将遗传物质传递到目标细胞中，用于多种医学和生物技术应用。这些病毒载体是基因治疗和基因编辑等先进治疗方法的关键工具。它们被设计为有效且安全的载体，用于传递治疗基因、纠正基因突变或操纵细胞过程。根据目标细胞、治疗基因和所需基因表现持续时间等因素，使用各种类型的病毒作为载体，包括腺相关病毒（AAV）、慢病毒和腺病毒。病毒载体的基因修饰消除或取代致病元件，同时掺入感兴趣的治疗基因。

主要市场驱动因素

市场概况
预测期 2024-2028
2022 年市场规模 52.2亿美元
2028 年市场规模 115.4亿美元
2023-2028 年复合年增长率 14.21%
成长最快的细分市场 腺相关病毒载体
最大的市场 北美洲

1. 病毒载体生产的开创性临床成功：

病毒载体生产的成功临床应用，其中病毒载体已有效地用于医学治疗和疗法，证明了基于病毒载体的方法治疗一系列疾病的潜力。例如，Spark Therapeutics 开发的 Luxturna 采用腺相关病毒 (AAV) 载体来治疗遗传性视网膜疾病。 Zolgensma 由 AveXis 开发，使用 AAV9 载体治疗脊髓性肌肉萎缩症。这些临床成功强调了基于病毒载体的疗法在治疗各种遗传性和获得性疾病方面的变革能力。

2.向量工程的进步：

载体工程的进步显着提高了用于基因治疗、基因编辑和疫苗开发的病毒载体的效率、安全性和特异性。对病毒载体的修饰增强了其组织靶向性，降低了免疫原性，并改善了细胞进入以实现有效的基因传递。此外，将 CRISPR-Cas9 等基因组编辑技术整合到病毒载体平台中可以实现精确的基因修饰。也正在探索从头开始设计的合成载体以用于客製化应用。

3. 病毒载体生产中不断发展的生物反应器技术：

生物反应器技术在生产用于基因治疗和基因编辑的病毒载体方面发挥着至关重要的作用。生物反应器为细胞培养、转染和载体生产提供受控环境，确保一致的品质和产量。一次性生物反应器因其易于使用和降低污染风险而受到关注。这些系统提高了可扩展性、产量和质量，同时减少了资源消耗和浪费。

主要市场挑战

1. 可扩展性和商业化：

从小规模实验室生产过渡到大规模商业化生产对病毒载体生产提出了挑战。在维持产品品质的同时扩大生产步骤需要优化细胞培养、转染、纯化和品质控制流程。设计符合监管标准的製造设施是资本密集的，与维持高生产力和产品完整性相关的挑战可能会导致商业化时间延长。

2. 商品成本与定价：

病毒载体生产的专业性以及品质控制措施和监管合规性导致了更高的生产成本。生产中使用的培养基、生长因子和其他原料可能很昂贵。专业任务需要熟练的专业人员，从而增加了劳动成本。这些因素共同影响基于病毒载体的疗法的可负担性和可近性。

主要市场趋势

1. 製造製程优化：

此领域强调改进和改进病毒载体生产工艺，以提高效率、降低成本、提高产量并确保品质稳定。优化包括增强下游和上游加工步骤、提高产量和维持产品品质。跨设施的标准化流程可确保一致性、合规性和品质。

2. 细分洞察：

AAV 领域的市场主导地位是由基因疗法中对 AAV 载体的需求不断增长所推动的。下游处理在维持载体品质和产量方面发挥着至关重要的作用，因此在工作流程部分中占据主导地位。由于遗传疾病持久解决方案的潜力，基因治疗应用领域蓬勃发展。研究机构是主要的最终用户，展示了对尖端疗法的承诺。

3. 区域洞察：

由于政府的大力支持、融资以及基因治疗和先进疗法的蓬勃发展的研发环境，北美在市场上处于领先地位。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球病毒载体生产市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按载体类型（腺病毒、AAV、慢病毒、逆转录病毒等）
    • 按工作流程（上游处理、载体扩增和扩展、载体恢復/收穫、下游处理、纯化、填充完成）
    • 按应用（基因和细胞疗法开发、疫苗开发、生物製药和药物发现、生物医学研究）
    • 依最终用途产业（製药和生物製药公司、研究机构）
    • 按公司划分 (2022)
    • 按地区
  • 市场地图

第 6 章：北美病毒载体生产市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按向量类型
    • 按工作流程
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 7 章：欧洲病毒载体生产市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按向量类型
    • 按工作流程
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章：亚太染料市场展望

  • 市场病毒载体生产及预测
    • 按价值
  • 市占率及预测
    • 按向量类型
    • 按工作流程
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国病毒载体生产
    • 印度病毒载体生产
    • 韩国病毒载体生产
    • 日本病毒载体生产
    • 澳洲病毒载体生产

第 9 章：南美洲病毒载体生产市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按向量类型
    • 按工作流程
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲病毒载体生产市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按向量类型
    • 按工作流程
    • 按应用
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非病毒载体生产
    • 沙乌地阿拉伯病毒载体生产
    • 阿联酋病毒载体生产

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：大环境分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • 商业概览
  • 公司概况
  • 产品与服务
  • 财务（上市公司）
  • 最近的发展
  • SWOT分析
    • Merck kgaa
    • Lonza
    • FUJIFILM Diosynth Biotechnologies USA
    • Cobra Biologics Ltd.
    • Thermofisher Scientific Inc.
    • Waisman Biomanufacturing
    • Genezen Laboratories
    • YPOSKESI
    • Advanced BioScience Laboratories, Inc. (ABL inc.)
    • Novasep Holding sas
    • Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
    • Takara Bio Inc.
    • RegenxBio, Inc.
    • Aldevron LLc.
    • Bluebird Bio Inc.

第 16 章：策略建议

简介目录
Product Code: 15912

The Global Viral Vector Production Market recorded a valuation of USD 5.22 Billion in 2022 and is expected to exhibit substantial growth during the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 14.21% and expected to reach USD 11.54 Billion through 2028. Viral vector production entails the creation and manufacturing of modified viruses, referred to as viral vectors, which are employed to deliver genetic material into target cells for diverse medical and biotechnological applications. These viral vectors are pivotal tools in advanced therapeutic approaches like gene therapy and gene editing. They are designed to be efficient and safe carriers for delivering therapeutic genes, rectifying genetic mutations, or manipulating cellular processes. Various types of viruses are utilized as vectors, including adeno-associated viruses (AAV), lentiviruses, and adenoviruses, based on factors such as target cells, the therapeutic gene, and desired gene expression duration. Genetic modification of viral vectors eliminates or replaces disease-causing elements while incorporating the therapeutic gene of interest.

The escalating triumph and approval of gene therapies for different diseases, such as genetic disorders and certain cancers, have boosted the demand for viral vectors as essential delivery tools for therapeutic genes. The rising prevalence of genetic disorders and diseases with a genetic component has spurred the requirement for targeted and effective treatments. Viral vectors offer a means to transport corrective or therapeutic genes into affected cells, making them a pivotal component in addressing such conditions. Research organizations, academic institutions, pharmaceutical firms, and biotechnology companies are channeling substantial investments into gene therapy research and development. This increased focus on the field is directly propelling the demand for viral vectors and their production.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 5.22 Billion
Market Size 2028USD 11.54 Billion
CAGR 2023-202814.21%
Fastest Growing SegmentAdenoassociated virus vectors
Largest MarketNorth America

1. Pioneering Clinical Success of Viral Vector Production:

The successful clinical applications of viral vector production, where viral vectors have been effectively used in medical treatments and therapies, have demonstrated the potential of viral vector-based approaches to address a spectrum of diseases. For instance, Luxturna, developed by Spark Therapeutics, employs adeno-associated virus (AAV) vectors to treat inherited retinal disease. Zolgensma, developed by AveXis, uses AAV9 vectors to treat spinal muscular atrophy. These clinical successes underscore the transformative capability of viral vector-based therapies in treating various genetic and acquired diseases.

2. Advancements in Vector Engineering:

Advances in vector engineering have significantly improved the efficiency, safety, and specificity of viral vectors used in gene therapy, gene editing, and vaccine development. Modifications to viral vectors enhance their tissue targeting, reduce immunogenicity, and improve cellular entry for efficient gene delivery. Furthermore, integration of genome editing technologies like CRISPR-Cas9 into viral vector platforms allows for precise genetic modifications. Synthetic vectors designed from scratch are also being explored for tailored applications.

3. Growing Bioreactor Technology in Viral Vector Production:

Bioreactor technology plays a crucial role in producing viral vectors for gene therapy and gene editing. Bioreactors provide controlled environments for cell culture, transfection, and vector production, ensuring consistent quality and yield. Single-use bioreactors have gained traction due to their ease of use and reduced contamination risk. These systems enhance scalability, yield, and quality while reducing resource consumption and waste.

Key Market Challenges

1. Scalability and Commercialization:

Transitioning from small-scale laboratory production to large-scale manufacturing for commercialization poses challenges in viral vector production. Scaling up production steps while maintaining product quality requires optimization of cell culture, transfection, purification, and quality control processes. Designing manufacturing facilities that adhere to regulatory standards is capital-intensive, and challenges associated with maintaining high productivity and product integrity can lead to extended timelines for commercialization.

2. Cost of Goods and Pricing:

The specialized nature of viral vector production, along with quality control measures and regulatory compliance, contributes to higher production costs. Culture media, growth factors, and other raw materials used in production can be expensive. Skilled professionals are required for specialized tasks, increasing labor costs. These factors collectively impact the affordability and accessibility of viral vector-based therapies.

Key Market Trends

1. Manufacturing Process Optimization:

The field emphasizes refining and improving viral vector production processes to enhance efficiency, reduce costs, increase yields, and ensure consistent quality. Optimization includes enhancing downstream and upstream processing steps, increasing yield, and maintaining product quality. Standardizing processes across facilities ensures uniformity, regulatory compliance, and quality.

2. Segmental Insights:

The market dominance of the AAV segment is driven by the increasing demand for AAV vectors in gene therapy. Downstream processing dominates the workflow segment due to its crucial role in maintaining vector quality and yield. The gene therapy application segment thrives due to the potential of durable solutions for genetic diseases. Research institutes are the dominant end users, showcasing the commitment to cutting-edge therapies.

3. Regional Insights:

North America leads the market due to robust government support, financing, and a thriving research and development environment for gene therapy and advanced therapeutics.

Key Market Players

  • Merck kgaa
  • Lonza
  • FUJIFILM Diosynth Biotechnologies U.S.A
  • Cobra Biologics Ltd.
  • Thermofisher Scientific Inc.
  • Waisman Biomanufacturing
  • Genezen Laboratories
  • YPOSKESI
  • Advanced BioScience Laboratories, Inc. (ABL inc.)
  • Novasep Holding s.a.s.
  • Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
  • Takara Bio Inc.
  • RegenxBio, Inc.
  • Aldevron LLc.
  • Bluebird Bio Inc.

Report Scope:

In this report, the Global Viral Vector Production Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Viral Vector Production Market, By Vector Type:

  • Adenovirus
  • AAV
  • Lentivirus
  • Retrovirus
  • Others

Viral Vector Production Market, By Workflow:

  • Upstream Processing
  • Vector amplification and expansion
  • Vector recovery/harvesting
  • Downstream Processing
  • Purification
  • Fill finish

Viral Vector Production Market, By Application:

  • Gene and Cell Therapy Development
  • Vaccine Development
  • Biopharmaceutical and Pharmaceutical Discovery
  • Biomedical Research

Viral Vector Production Market, By End User:

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes

Global Viral Vector Production Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Viral Vector Production Market.

Available Customizations:

  • Global Dyes Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Viral Vector Production Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Vector Type (Adenovirus, AAV, Lentivirus, Retrovirus, others)
    • 5.2.2. By Workflow (Upstream Processing, Vector amplification and expansion, Vector recovery/harvesting, Downstream Processing, Purification, Fill finish)
    • 5.2.3. By Application (Gene and Cell Therapy Development, Vaccine Development, Biopharmaceutical and Pharmaceutical Discovery, Biomedical Research)
    • 5.2.4. By End-Use Industry (Pharmaceutical and Biopharmaceutical Companies, Research Institutes)
    • 5.2.5. By Company (2022)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America Viral Vector Production Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Vector Type
    • 6.2.2. By Workflow
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Viral Vector Production Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Vector Type
        • 6.3.1.2.2. By Workflow
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Mexico Viral Vector Production Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Vector Type
        • 6.3.2.2.2. By Workflow
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Canada Viral Vector Production Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Vector Type
        • 6.3.3.2.2. By Workflow
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe Viral Vector Production Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Vector Type
    • 7.2.2. By Workflow
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Viral Vector Production Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Vector Type
        • 7.3.1.2.2. By Workflow
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. Germany Viral Vector Production Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Vector Type
        • 7.3.2.2.2. By Workflow
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Viral Vector Production Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Vector Type
        • 7.3.3.2.2. By Workflow
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Viral Vector Production Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Vector Type
        • 7.3.4.2.2. By Workflow
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Viral Vector Production Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Vector Type
        • 7.3.5.2.2. By Workflow
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia-Pacific Dyes Market Outlook

  • 8.1. Market Si Viral Vector Production ze & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Vector Type
    • 8.2.2. By Workflow
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Viral Vector Production Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Vector Type
        • 8.3.1.2.2. By Workflow
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India Viral Vector Production Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Vector Type
        • 8.3.2.2.2. By Workflow
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. South Korea Viral Vector Production Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Vector Type
        • 8.3.3.2.2. By Workflow
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. Japan Viral Vector Production Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Vector Type
        • 8.3.4.2.2. By Workflow
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Viral Vector Production Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Vector Type
        • 8.3.5.2.2. By Workflow
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. South America Viral Vector Production Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Vector Type
    • 9.2.2. By Workflow
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Viral Vector Production Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Vector Type
        • 9.3.1.2.2. By Workflow
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Viral Vector Production Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Vector Type
        • 9.3.2.2.2. By Workflow
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Viral Vector Production Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Vector Type
        • 9.3.3.2.2. By Workflow
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. Middle East and Africa Viral Vector Production Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Vector Type
    • 10.2.2. By Workflow
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Viral Vector Production Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Vector Type
        • 10.3.1.2.2. By Workflow
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Viral Vector Production Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Vector Type
        • 10.3.2.2.2. By Workflow
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Viral Vector Production Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Vector Type
        • 10.3.3.2.2. By Workflow
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Merck kgaa
    • 15.6.2. Lonza
    • 15.6.3. FUJIFILM Diosynth Biotechnologies U.S.A
    • 15.6.4. Cobra Biologics Ltd.
    • 15.6.5. Thermofisher Scientific Inc.
    • 15.6.6. Waisman Biomanufacturing
    • 15.6.7. Genezen Laboratories
    • 15.6.8. YPOSKESI
    • 15.6.9. Advanced BioScience Laboratories, Inc. (ABL inc.)
    • 15.6.10. Novasep Holding s.a.s.
    • 15.6.11. Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
    • 15.6.12. Takara Bio Inc.
    • 15.6.13. RegenxBio, Inc.
    • 15.6.14. Aldevron LLc.
    • 15.6.15. Bluebird Bio Inc.

16. Strategic Recommendations